Monthly or Weekly Supplementation with Cholecalciferol 20,000 IU in People Living with HIV: Results from a Nested Cohort Study

Table 1

Characteristics of the subgroup per supplementation regimen at baseline and after 12 months of supplementation ([S] = serum concentration).

		Unit	Weekly	Monthly	P value
			(N=84)	(N=40)
	Age	years (IQR)	48 (40–57)	46 (39–55)	0.234
	Gender (male)	N (%)	67 (79.8)	31 (77.5)	0.772
	Ethnicity (African)	N (%)	9 (10.7)	8 (20.0)	0.160
	Creatinine [S]	mg/dL (IQR)	0.9 (0.8–1.1)	0.9 (0.7–1.1)	0.212
	Viral load	copies/mL	19 (19–19)	283 (19–8,793)	<0.001
	Viral load <200/mL	N (%)	81 (96.4)	20 (50.0)	<0.001
	CD4 cell count (absolute)	cells/μL (IQR)	632 (496–861)	395 (183–610)	<0.001
	CD4 cell count (relative)	% (IQR)	31.5 (24.0–37.0)	21.5 (11.3–32.0)	<0.001
	Missing data	N (%)	-	-
	HIV risk group: MSM	N (%)	49 (48.3)	11 (27.5)	0.001
ART AT BASELINE	Protease Inhibitor-based ART Regimen	N (%)	33 (39.3)	13 (32.5)	0.465
	Efavirenz-based ART	N (%)	15 (17.9)	9 (22.5)	0.541
	Tenofovir disoproxil fumarate-based ART	N (%)	52 (61.9)	27 (67.5)	0.545
BASELINE	25(OH)D [S]	ng/mL (IQR)	12 (9–16)	8 (5–13)	<0.001
	25(OH)D <10 ng/dL	N (%)	27 (32.1)	26 (65.0)	0.001
	Missing data	N (%)	-	-
	Calcium [S]	mg/dL (IQR)	2.26 (2.18–2.32)	2.31 (2.26–2.39)	0.020
	Missing data	N (%)	-	17 (42.5%)
	Phosphate [S]	mg/dL (IQR)	3.0 (2.7–3.4)	3.3 (3.0–3.8)	0.019
	Missing data	N (%)	-	5 (12.5%)
	AP [S]	IU/mL (IQR)	88 (72–108)	84 (60–103)	0.205
	Missing data	N (%)	-	-
AFTER 12 MONTHS	25(OH)D [S]	ng/mL (IQR)	28 (21–36)	24 (18–30)	0.004
	25(OH)D ≥30 ng/mL	N (%)	39 (46.4)	9 (22.5)	0.011
	Calcium [S]	mg/dL (IQR)	2.28 (2.23–2.35)	2.39 (2.35–2.48)	<0.001
	Missing data	N (%)	-	5 (12.5%)
	Phosphate [S]	mg/dL (IQR)	3.2 (2.8–3.6)	3.3 (3.0–3.7)	0.122
	Missing data	N (%)	-	2 (5.0%)
	AP [S]	IU/mL (IQR)	85 (70–104)	78 (67–100)	0.211
	Missing data	N (%)	-	-